X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse Abbott India with ACTAVIS INC. - US - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ABBOTT INDIA vs ACTAVIS (US) - Comparison Results

ABBOTT INDIA    Change

Formerly known as Knoll Pharmaceuticals Limited, Abbott India Limited (AIL) is a subsidiary of Abbott Capital India Limited in which the latter holds about 69% stake. It is involved in the discovery, development, manufacture and marketing of pharmace... More

ACTAVIS (US)
   Change

Actavis, Inc. is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products. It develops, manufactures and market generic, branded generic, legacy brands and Over... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 ABBOTT INDIA   ACTAVIS
EQUITY SHARE DATA
    ABBOTT INDIA
Mar-16
ACTAVIS
Dec-14
ABBOTT INDIA/
ACTAVIS
5-Yr Chart
Click to enlarge
High Rs6,01517,410-   
Low Rs3,70710,620-   
Sales per share (Unadj.) Rs1,236.93,135.1-  
Earnings per share (Unadj.) Rs122.2-391.2-  
Cash flow per share (Unadj.) Rs129.0287.6-  
Dividends per share (Unadj.) Rs35.000-  
Dividend yield (eoy) %0.70-  
Book value per share (Unadj.) Rs521.26,799.9-  
Shares outstanding (eoy) m21.25265.90-   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.94.5 87.9%   
Avg P/E ratio x39.8-35.8 -111.1%  
P/CF ratio (eoy) x37.748.7 77.4%  
Price / Book Value ratio x9.32.1 452.5%  
Dividend payout %28.60-   
Avg Mkt Cap Rs m103,2963,726,554 2.8%   
No. of employees `0003.021.6 13.7%   
Total wages/salary Rs m3,3700-   
Avg. sales/employee Rs Th8,891.838,593.4 23.0%   
Avg. wages/employee Rs Th1,140.00-   
Avg. net profit/employee Rs Th878.3-4,816.0 -18.2%   
INCOME DATA
Net Sales Rs m26,284833,617 3.2%  
Other income Rs m504-2,081 -24.2%   
Total revenues Rs m26,789831,536 3.2%   
Gross profit Rs m3,665107,090 3.4%  
Depreciation Rs m144180,508 0.1%   
Interest Rs m826,294 0.0%   
Profit before tax Rs m4,017-101,793 -3.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-7,467 0.0%   
Tax Rs m1,421-5,233 -27.2%   
Profit after tax Rs m2,596-104,027 -2.5%  
Gross profit margin %13.912.8 108.6%  
Effective tax rate %35.45.1 688.0%   
Net profit margin %9.9-12.5 -79.2%  
BALANCE SHEET DATA
Current assets Rs m14,446439,209 3.3%   
Current liabilities Rs m4,725320,313 1.5%   
Net working cap to sales %37.014.3 259.3%  
Current ratio x3.11.4 223.0%  
Inventory Days Days5158 88.6%  
Debtors Days Days2066 29.5%  
Net fixed assets Rs m1,113101,793 1.1%   
Share capital Rs m2130-   
"Free" reserves Rs m10,8080-   
Net worth Rs m11,0761,808,084 0.6%   
Long term debt Rs m0947,472 0.0%   
Total assets Rs m16,2413,313,624 0.5%  
Interest coverage x497.0-2.9 -17,307.6%   
Debt to equity ratio x00.5 0.0%  
Sales to assets ratio x1.60.3 643.3%   
Return on assets %16.0-2.3 -683.6%  
Return on equity %23.4-5.8 -407.4%  
Return on capital %36.3-3.0 -1,207.0%  
Exports to sales %0.60-   
Imports to sales %12.60-   
Net fx Rs m-3,6590-   
CASH FLOW
From Operations Rs m2,514143,148 1.8%  
From Investments Rs m-800-342,752 0.2%  
From Financial Activity Rs m-803192,577 -0.4%  
Net Cashflow Rs m912-7,027 -13.0%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for ACTAVIS (US) is United States Dollars. All data has been converted at 63.82 Rs / USD

Compare ABBOTT INDIA With: MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  

Compare ABBOTT INDIA With: LUPIN LTD  FDC LTD.  CADILA HEALTHCARE  IPCA LABS  PFIZER  



Today's Market

Sensex Breaches 36,000 Mark; ONGC Nears 52-Week High(Closing)

The NSE Nifty on Tuesday sailed past the 11,000 mark, while the BSE Sensex breached the 36,000 level for the first time after an IMF report showed India was set to regain.

Related Views On News

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

Lupin: US Markets Drags down Revenues and Net Profits (Quarterly Results Update - Detailed)

Nov 2, 2017

Domestic markets registers robust growth in the quarter

More Views on News

Most Popular

Mutual Funds Clearly Tell Us That There is a Bubble in the Stock Market(Vivek Kaul's Diary)

Jan 11, 2018

The maximum amount of money ever has come into equity mutual funds during the current financial year.

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Did GST and Notebandi Help? Sherlock Holmes Finds Out...(The 5 Minute Wrapup)

Jan 13, 2018

Discussions with my cousin helped me understand the situation on Ground Zero - after the demonetization and GST upheaval. Here's what that means for listed companies...

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

Nirvana denied: Has Value Failed?(The Honest Truth)

Jan 13, 2018

Should investors choose growth over value this year?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ABBOTT INDIA SHARE PRICE


Jan 23, 2018 (Close)

TRACK ABBOTT INDIA

  • Track your investment in ABBOTT INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ABBOTT INDIA 5-YR ANALYSIS

COMPARE ABBOTT INDIA WITH

MARKET STATS